Horizon Ramps Teprotumumab Launch Plans Into High Gear

With US FDA action on teprotumumab anticipated in March, Horizon has assembled a 100-person commercial team to begin educating physicians and payers on the rare autoimmune condition thyroid eye disease (TED).

Manual Gearbox - fast motion concept - Image
Horizon looks to drive growth with the launch of teprotumumab • Source: Shutterstock

Horizon Therapeutics PLC is building out its commercial plans for the launch of teprotumumab for the rare autoimmune condition thyroid eye disease (TED) in early 2020. Teprotumumab is pending at the US Food and Drug Administration under a priority review, with an action date of 8 March.

CEO Timothy Walbert outlined the company's launch strategy for the insulin-like growth factor 1 receptor (IGF-1R) inhibitor during the company's...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.